[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368383-105":59,"doc-detail-368383-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","distinct-dysregulated-pathways-in-sporadic-and-lynch-syndrome-associated-colorectal-cancer-offer-insights-for-targeted-treatment","Distinct dysregulated pathways in sporadic and Lynch syndrome-associated colorectal cancer offer insights for targeted treatment","","Lynch syndrome (LS) is a hereditary disorder that elevates colorectal cancer (CRC) risk through constitutional pathogenic variants in mismatch repair (MMR) genes, and somatic mutations in the same genes lead to MMR deficiency. The mechanisms driving tumor development remain unclear, motivating this study to identify distinct molecular drivers in LS-associated and sporadic CRC. PI3K–Akt signaling is found to be dysregulated in LS-associated CRC, whereas Wnt signaling predominates in sporadic CRC. The results suggest therapeutic opportunities: PI3K–Akt pathway inhibitors (e.g., taselisib) for LS-associated patients with high pathway dependency and Wnt pathway inhibitors (e.g., XAV939) for sporadic CRC, supporting targeted approaches tailored to CRC subtype-specific oncogenic pathways.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/distinct-dysregulated-pathways-in-sporadic-and-lynch-syndrome-associated-colorectal-cancer-offer-insights-for-targeted-treatment/368383/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/distinct-dysregulated-pathways-in-sporadic-and-lynch-syndrome-associated-colorectal-cancer-offer-insights-for-targeted-treatment/368383.png","ImageObject",300,407,{"name":92,"@type":93},"Margaret","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What genetic mechanism underlies Lynch syndrome-related colorectal cancer in this study?","Question",{"text":112,"@type":113},"Lynch syndrome arises from constitutional pathogenic variants in MMR genes, and additional somatic mutations can cause MMR deficiency through loss of the normal allele, leading to mutation accumulation and CRC development.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which signaling pathway is dysregulated in LS-associated colorectal cancer?",{"text":117,"@type":113},"PI3K–Akt signaling is dysregulated in LS-associated colorectal cancer.",{"name":119,"@type":110,"acceptedAnswer":120},"How do the findings suggest targeted therapies for different CRC subtypes?",{"text":121,"@type":113},"For LS-associated CRC with high pathway dependency, PI3K–Akt pathway inhibitors such as taselisib are suggested; for sporadic CRC, Wnt pathway inhibitors such as XAV939 are proposed.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368383,1790266383,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},137451207643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","RESEARCH ARTICLE  \nDistinct dysregulated pathways in sporadic and Lynch syndrome-associated colorectal cancer offer insights for targeted treatment  \nMay J. Krause 1 , Musalula Sinkala2  and Raj Ramesar 1   \n1 UCT MRC Genomic and Precision Medicine Research Unit, Division of Human Genetics, Department of Pathology, Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, South Africa  \n2 Computational Biology Division, Department of Integrative Biomedical Sciences, School of Health Sciences, University of Cape Town, South Africa  \nCorrespondence  \nR. Ramesar, UCT MRC Genomic and Precision Medicine Research Unit, Division of Human Genetics, Department of Pathology, Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory, Cape Town 7925, South Africa  \nTel: 021 406 6337  \nE-mail: [raj.ramesar@uct.ac.za](raj.ramesar@uct.ac.za)  \n(Received 13 November 2024, revised 22 January 2025, accepted 28 January 2025, available online 20 February 2025)  \nLynch syndrome (LS) is a hereditary disorder that increases the risk of colorectal cancer (CRC) due to constitutional pathogenic variants in mismatch repair (MMR) genes. When coupled with somatic mutations in the same gene, MMR deﬁciency occurs. However, the mechanisms driving cancer development remain unclear. This study aimed to identify distinct molecular drivers in LS-associated and sporadic CRC. We found that PI3K–Akt signalling is dysregulated in LS-associated CRC, while Wnt signalling predominates in sporadic CRC. Moreover, our ﬁndings highlight the therapeutic potential of PI3K–Akt pathway inhibitors, such as taselisib, for LS-associated CRC patients with high pathway dependency. Similarly, Wnt signalling pathway inhibitors, such as XAV939, offer a promising therapeutic approach for sporadic CRC. These ﬁndings underscore the importance of understanding the biological basis of disease for developing targeted therapies tailored to CRC subtype-speciﬁc oncogenic pathways.  \ndoi:10.1002/1873-3468.70010  \nEdited by Angeliki Malliri  \nKeywords: bioinformatics; cancer; colorectal cancer; dysregulated signalling pathways; Lynch syndrome; mismatch repair  \nLynch syndrome (LS), previously known as hereditary nonpolyposis colorectal cancer, is a hereditary disorder that signiﬁcantly increases the risk of developing multiple types of cancers, including colonic, rectal, endometrial, small intestinal, ovarian, hepatobiliaryand urothelial cancers [1,2] . LS is the most common hereditary colorectal cancer (CRC) syndrome, accounting for approximately 3–5% of all CRC cases [3] . This autosomal dominant condition is  \ncharacterised by early cancer onset and results from constitutional pathogenic variants affecting one of four DNA mismatch repair (MMR) genes (MLH1, MSH2, MSH6 or PMS2), including deletions in the 30 region of EPCAM, leading to a loss of MSH2 expression [4,5] .  \nThe MMR system plays a crucial role in maintaining genetic stability by identifying and repairing errors such as mismatches, and small insertions/deletions  \nAbbreviations  \ncAMP, cyclic adenosine monophosphate; CRC, colorectal cancer; DEGs, differentially expressed genes; DGE, differential gene expression analysis; dMMR, deﬁcient mismatch repair; ECM, extracellular matrix; GDSC, Genomics of Drug Sensitivity in Cancer; GEO, Gene Expression Omnibus; GSEA, gene set enrichment analysis; IL-17, interleukin-17; KEGG, Kyoto Encyclopaedia of Genes and Genomes; LLS, likely Lynch syndrome; LS, Lynch syndrome; LSp, likely sporadic; MMR, mismatch repair; MSI, microsatellite instability; MSS, microsatellite stable; OGs, oncogenes; PI3K-Akt, phosphatidylinositol 30-kinase-protein kinase B; PRC2, polycomb repressive complex 2; RNA-seq, RNA sequencing; SMOTE, Synthetic Minority Over-sampling Technique; TCGA, The Cancer Genome Atlas; TMB, tumour mutation burden; TSG, tumour suppressor genes; WES, whole-exome sequencin","cbCaiqxUThAWTLjd","https://ap.wps.com/l/cbCaiqxUThAWTLjd","pdf",3849166,23,"English","# Introduction\n# Lynch syndrome and mismatch repair deficiency\n# Distinct molecular drivers in LS-associated vs sporadic CRC\n# Therapeutic implications for targeted treatment","[{\"question\":\"What genetic mechanism underlies Lynch syndrome-related colorectal cancer in this study?\",\"answer\":\"Lynch syndrome arises from constitutional pathogenic variants in MMR genes, and additional somatic mutations can cause MMR deficiency through loss of the normal allele, leading to mutation accumulation and CRC development.\"},{\"question\":\"Which signaling pathway is dysregulated in LS-associated colorectal cancer?\",\"answer\":\"PI3K–Akt signaling is dysregulated in LS-associated colorectal cancer.\"},{\"question\":\"How do the findings suggest targeted therapies for different CRC subtypes?\",\"answer\":\"For LS-associated CRC with high pathway dependency, PI3K–Akt pathway inhibitors such as taselisib are suggested; for sporadic CRC, Wnt pathway inhibitors such as XAV939 are proposed.\"}]","Distinct dysregulated pathways in sporadic and Lynch syndrome-associated colorectal cancer offer insights for targeted treatment | PDF",1790176645,58,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5858e8339700b02db393b8105fe628b8.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d1674e43f2ff230bf3d45284b251aece.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8e5e0bfa72a5441547e1a1ee9f2dde51.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/804678de97d1cf7d8506ed6873677968.webp",980,1287]